EKF’s H1 trading update indicates profits will be heavily (i.e. almost all) H2 weighted due to some tender delays (again). Some of this is due to the Mexican orders from last year and some new opportunities, e.g. a large potential order in the Middle East for the Quo-test product. Of more interest is the result of the strategy review. A few options are still available, but the most likely seems to be a $110m offer on the table for the Point-of-Care business, which looks to have put a floor under the current share price, with the Molecular Diagnostics division effectively in for nothing.
